JP2011509071A5 - - Google Patents

Download PDF

Info

Publication number
JP2011509071A5
JP2011509071A5 JP2010536200A JP2010536200A JP2011509071A5 JP 2011509071 A5 JP2011509071 A5 JP 2011509071A5 JP 2010536200 A JP2010536200 A JP 2010536200A JP 2010536200 A JP2010536200 A JP 2010536200A JP 2011509071 A5 JP2011509071 A5 JP 2011509071A5
Authority
JP
Japan
Prior art keywords
ibd
expression
medicament according
medicament
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010536200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509071A (ja
Filing date
Publication date
Priority claimed from PCT/US2008/064562 external-priority patent/WO2008147900A2/en
Application filed filed Critical
Priority claimed from PCT/US2008/085045 external-priority patent/WO2009073565A2/en
Publication of JP2011509071A publication Critical patent/JP2011509071A/ja
Publication of JP2011509071A5 publication Critical patent/JP2011509071A5/ja
Pending legal-status Critical Current

Links

JP2010536200A 2007-11-29 2008-11-26 炎症性腸疾患のための遺伝子発現マーカー Pending JP2011509071A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99120307P 2007-11-29 2007-11-29
PCT/US2008/064562 WO2008147900A2 (en) 2007-05-22 2008-05-22 Gene expression markers for inflammatory bowel disease
US19226808P 2008-09-17 2008-09-17
PCT/US2008/085045 WO2009073565A2 (en) 2007-11-29 2008-11-26 Gene expression markers for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2011509071A JP2011509071A (ja) 2011-03-24
JP2011509071A5 true JP2011509071A5 (https=) 2013-01-17

Family

ID=40459795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536200A Pending JP2011509071A (ja) 2007-11-29 2008-11-26 炎症性腸疾患のための遺伝子発現マーカー

Country Status (9)

Country Link
EP (1) EP2261367A3 (https=)
JP (1) JP2011509071A (https=)
KR (1) KR20110015409A (https=)
CN (1) CN101970689A (https=)
AU (1) AU2008334095A1 (https=)
CA (1) CA2706729A1 (https=)
IL (2) IL206014A (https=)
MX (1) MX2010005893A (https=)
WO (1) WO2009073565A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639710A (zh) * 2009-07-20 2012-08-15 基因泰克公司 克罗恩病的基因表达标记
EP2486130A1 (en) * 2009-10-06 2012-08-15 Tallinn University Of Technology Inhibition or activation of serine/threonine ulk3 kinase activity
WO2011127351A1 (en) * 2010-04-09 2011-10-13 Exagen Diagnostics, Inc. Biomarkers for ulcerative colitis and crohn's disease
CA2801575A1 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
EP3186391B1 (en) * 2014-08-28 2020-05-27 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Methods and kit for identification of cancer
JP6192177B2 (ja) * 2015-05-25 2017-09-06 ヤマサ醤油株式会社 炎症性腸疾患のバイオマーカーとしてのs100a9の使用
US11186872B2 (en) * 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
EP3602041A4 (en) * 2017-03-23 2021-01-13 Meharry Medical College METHODS OF DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASE
EP3641778A4 (en) * 2017-06-20 2021-03-31 Meharry Medical College TARGETED DEFA5 ANTIBODY AND TESTING PROCEDURE FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE INTESTINAL DISEASES
US11566049B2 (en) * 2018-03-29 2023-01-31 Lateral IP Pty Ltd Cyclic peptides and uses thereof
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
WO2020000436A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人INDO基因的gRNA导向序列及其应用
EP3821246A4 (en) * 2018-07-15 2022-06-22 Rambam Med-Tech Ltd. Determining responders to inflammation treatment
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
US12293809B2 (en) * 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
JP2021185817A (ja) * 2020-05-29 2021-12-13 独立行政法人国立病院機構 バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用
WO2025029562A1 (en) * 2023-07-28 2025-02-06 The Johns Hopkins University Dna vaccines for eliciting t cell immunity in the lung
CN119236059B (zh) * 2024-10-11 2025-04-18 广东医科大学附属医院 Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用
CN119798401B (zh) * 2024-12-30 2025-10-10 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0527283B1 (en) 1991-08-12 1997-11-26 Societe Des Produits Nestle S.A. Food composition
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CA2362929A1 (en) * 1999-03-04 2000-09-08 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
AU784861B2 (en) * 1999-10-21 2006-07-06 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1844158A4 (en) * 2004-12-06 2010-09-08 Univ Johns Hopkins BIOMARKER FOR INFLAMMATORY ENDURANCE
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
SI2257643T1 (sl) * 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni

Similar Documents

Publication Publication Date Title
JP2011509071A5 (https=)
JP2012533322A5 (https=)
Atreya et al. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF?
Zhang et al. A key genetic factor governing arabinan utilization in the gut microbiome alleviates constipation
Mar et al. IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans
CA2812940A1 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
CN102586408B (zh) 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
US20190004066A1 (en) Methods of treating liver fibrosis
JP2011511804A5 (https=)
CN114250221B (zh) SARS-CoV-2 RBD中和核酸适体的筛选方法及核酸适体
Hu et al. A functional variant of mi RNA‐149 confers risk for allergic rhinitis and comorbid asthma in Chinese children
Tillisch et al. 589 modulation of the brain-gut axis after 4-week intervention with a probiotic fermented dairy product
Anbazhagan et al. Translational repression of SLC26A3 by miR-494 in intestinal epithelial cells
Murdaca et al. The role of skin and gut microbiome and epigenetic modifications in skin-autoimmune disorders
Hariyanto et al. The use of ACE inhibitor/ARB in SARS-CoV-2 patients: a comprehensive narrative review
JP2010508025A5 (https=)
Hu et al. Impact of IL-22 gene polymorphism on human immunodeficiency virus infection in Han Chinese patients
JP2012524248A5 (https=)
JP2009523004A5 (https=)
Gao et al. Epigenetic upregulation of ssc-miR-124a following treatment with Clostridium perfringens beta2-toxin attenuates both apoptosis and inflammation in intestinal porcine epithelial cells
Tree et al. The impact of “omic” and imaging technologies on assessing the host immune response to biodefence agents
CN104099329A (zh) 一种与高血压易感性相关的基因位点及其检测方法
Stone UT-34: a promising new AR degrader
CA2864133A1 (en) Methods related to treatment of inflammatory diseases and disorders
Bai From Molecules to Medicine: Expanding the Therapeutic Streetlight for Inflammatory Bowel Diseases